The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2018 (PDF).
This issue advises clinicians that head lice treatments carry a risk of serious burns if treated hair is exposed to open flames or other sources of ignition. Eight cases of serious burns associated with Hedrin® 4% cutaneous solution have been reported to the MHRA since the product was licensed in 2005. Parents, carers and the people with head lice should be advise that they should not smoke around treated hair and that it should be kept away from open flames or other sources of ignition, including in the morning after overnight application until hair is washed.
The issue also advises readers that GP practices that share information with the Clinical Practice Research Datalink can now access free quality improvement reports designed to improve patient safety and the quality of prescribing. The reports are also likely to be useful at annual appraisals.
This issue also contains a summary of recent drug and device alerts, including details of the ellaOne® pregnancy registry and details of the restrictions on the use of ulipristal acetate (Esmya®) following reports of liver injury.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.